THE UNIVERSITY OF ALABAMA AT BIRMINGHAM

Knowledge that will change your world

## Metabolite identification in metabolomics: Metlin Database and interpretation of MSMS spectra

Jeevan K. Prasain, PhD Department of Pharmacology and Toxicology, UAB jprasain@uab.edu







### Keys to identifying chemical structures (putative/definitive) by mass spectrometry

- $\circ~$  Retention time in LC
- Accurate mass
- Isotope distribution
- Nitrogen rule
- Fragmentation pattern of a precursor ion
- Product/precursor ion intensity ratio
- Comparison with authentic standards (definitive)

Moco et al. Trends in Analytical Chemistry, 2007

# **LCMS-based metabolis**Detection of intact molecular ions [M+H]<sup>+</sup>/[M-H]<sup>-</sup> is possible with soft ionization such as ESI High mass accuracy of many instruments (<5 ppm, 0.005%) helps identify isobaric compounds</li> Enables the separation of complex mixtures and identification of molecular weight of pure compounds Substructures of unknown metabolite may be proposed on the basis of LC retention time, exact mass measurement and interpretation of signature ions upon MS/MS of a precursor ion

# Platform to process untargeted metabolomic data

- **XCMS** (developed by the Siuzdak Lab at the Scripps Research Institute) Online, is a web-based version that allows users to easily upload and process LC-MS data. It is a bioinformatics platform to identify endogenous metabolites.
- METLIN (<u>http://metlin.scripps.edu</u>) is a metabolite database for metabolomics containing 1 million compounds and it also has comprehensive tandem mass spectrometry data on over 10,000 molecules at different collision energies.
  - Provides an annotated list of known metabolites, their masses, chemical forms and structures.



METLIN has multiple searching capabilities including single, batch, precursor ion, neutral loss, accurate mess, and fragment searches. The popular similarly search algorithm for unknown characterization, another METLIN search option, originated on METLIN in 2008. METLIN represents the largest MS/MS collection of data with the database generated at multiple collision energies and in positive and negative ionization modes. The data is generated on multiple instrument types including SOEX, Aglient, Bruker and Waters OTCP mass spectrometers. Created in 2003, METLIN now includes over a million molecules ranging from lipids, steroids, pient & bacteria metabolites, small peptides, carbohydrates, exogenous drugs/imetabolites, central carbon metabolites and texicants. The metabolites and other small molecules have been individually analyzed to provide both empirical and in silico MS/MS data.



METUN has multiple searching capabilities including single, batch, precursor ion, neutral loss, accurate mass, and fagment searches. The popular similarity search algorithm for unknown characterization, another METUN search option, originated on METUN in 2008. METLIN represents the largest MS/MS collection of data with the database generated at multiple collision energies and in positive and negative ionization modes. The data is generated on multiple instrument types including SCIEX, Aglent, Bruker and Waters QTOF mass spectrometers.

Created in 2003, METLIN now includes over a million molecules ranging from [pids, strends, plant & bacteria metabolites, small paptides, carobydrates, ecogenous duyd/metabolites, central carbon metabolites and toxicants. The metabolites and other small molecules have been individually analyzed to provide both merifical and in silico MS/MS data.







|            |                               | m                   | eta             | ac      | )0        | iom                | IC                    | aa          | [a   |                              |               |                 |               |
|------------|-------------------------------|---------------------|-----------------|---------|-----------|--------------------|-----------------------|-------------|------|------------------------------|---------------|-----------------|---------------|
|            |                               |                     |                 |         |           |                    |                       |             |      |                              | tim           | tora Resulta    |               |
| Quick Comp | pound Search:                 | 12                  | learth    Clear |         |           |                    |                       |             |      | Pee                          | H CICK ON & I | ow to view la   | ature details |
| (08r10513) | 13 CRUEES, URINE, NEC, MINC   | 016.                |                 |         |           |                    |                       |             |      | Feature #6<br>m/r = 250.0048 |               |                 |               |
| 2 A 40     | stumme of Show Instance peaks | Page at 17 at a 177 |                 |         |           |                    | View 1 - 100 of 2 611 |             |      |                              | Retention 1   | Time (min):     | 11.23         |
| Instantic  | fold peaks updown             | named               | rimed           | masint  | dataset1  | dataset2 inchoses  | adducts peaks         | ri usernote |      | _                            |               | EIC             |               |
| +          | 2.1.2.48267e DOWN             | 284.1884            | 19.29           | 1.828   | 31,233    | 14.964             | 100                   |             | 1    | 1                            |               | an Lineacher    | 1 Destaurs    |
| 2          | 2.4.4.4290fe DOWN             | 263 1853            | 10.01           | 6.460   | 118.348   | 48,052             | 100                   |             | 1    | 1                            | - Orub        | DS_UnreGroup    | 2_NegMode     |
| 4          | 2.9 1.23683e DOMM             | 245.1714            | 19.55           | 1.029   | 11.013    | 3.754              | 78                    |             |      | 10                           |               |                 |               |
| 8          | 1.0.5.65500e UP               | 259.0049            | 11.23           | 47,545  | 197,968   | 307.692 (9256)     | - 52                  |             |      | 1.                           |               | 1               |               |
| 1          | 1.5 8.13982e DOWN             | 458.1997            | 12.55           | 3,657   | 31,121    | 18,196             | 6                     |             |      | 8.                           |               | A               | FA            |
| - 8        | 1.5 1.044444 DOWN             | 289.1533            | 1872            | 13.559  | 196.876   | 122,396            | 40                    |             |      | 2                            | -             | 1               | 29 8          |
| .9         | 2.5 1.19250e DOWN             | 209.0479            | 11.88           | 9,315   | 58,693    | 23,544             | 43                    |             |      | 2.3                          |               | 1               | 1             |
| 10         | 17.121480e UP                 | 290 0074            |                 | 5344    | 27,029    | 45.321             | 50                    |             |      |                              | 10.5<br>Rater | tion Time (minu | ultrei IZ.D   |
|            | 2.7 1.545448 DOWN             | 342.1817            | 13.29           | 1,403   | 21,839    | 8.035              | 3                     |             |      |                              | -             |                 | -             |
| 12         | 7.0.3 497209 DOWN             | 214.1425            | 15.07           | 1,007   | 103,291   | 14,253             | 100                   |             | - 81 |                              | Box-and       | Whesker         | Plot          |
| 14         | 3.1.5.48334 DOWN              | 222.5727            | 14.25           | 1.031   | 8.420     | 1.129              |                       |             |      |                              |               |                 |               |
| 15         | 19.7 6.46515e DOWN            | 262 1442            | 20.74           | 12.214  | 79.549    | 4.045              | 112                   |             |      | N                            | nt a sign     | ificant.        | feeture       |
| 18.        | 2.0.7.05382e/UP               | 357.0017            | 6.56            | 64,588  | 152.345   | 321.860 [144][N) - | 68                    |             |      |                              | 10.0          |                 |               |
| - 17       | 1.8 7.90761e DOWN             | 307.1733            | 14.01           | 3,047   | 38,707    | 22,113             | 17                    |             |      |                              |               |                 |               |
| 18         | 1.5 8.56842e DOWN             | 222.0736            | 12.94           | 4,470   | 25.440    | 23.745             |                       |             |      |                              |               |                 |               |
| 19         | 5.6 9.67267e DOWN             | 248.1261            | 19.52           | 6,452   | 44,193    | 7,890              | 78                    |             |      |                              | See.          | parterialist to | id interio    |
| 22         | 1.9 9.93395e DOWN             | 253.0369            | 13.74           | 139,227 | 1,061,319 | 563.804 (79gM)-    | 15                    |             |      | andterminations              |               |                 |               |
| 21         | 4.2 1.07130e UP               | 342.0106            | 18.78           | 1,834   | 3,852     | 16,140             | 119                   |             |      |                              |               |                 |               |
| 22         | 1.8 1.2 1423 # UP             | 262 (0230           | 10.72           | 17,832  | 37,542    | 64,807             | 40                    |             |      |                              |               |                 |               |
| 24         | 2.5 1.50578e DOWN             | 587.3766            | 19.95           | - 254   | 7,036     | 2.762              | 31                    |             |      |                              |               |                 |               |
| 10         | A T T SERVICE                 | 228.1000            | 10.74           | 8,872   | 54 774    | 17 184             | 129                   |             |      |                              |               |                 |               |
| 26         | 1.6.2 M376e DOWN              | 334 1315            | 14.67           | 5,892   | 165.657   | 101 718            | 28                    |             |      |                              |               |                 |               |
| 29         | 5.5 2 17097e DOWN             | 443.1640            | 11.60           | 8,675   | 102.105   | 18.013 (212)04     | 97                    |             |      |                              |               |                 |               |
| 31         | 1.8-2.74162# DOWN             | 263.1134            | 9.95            | 9.372   | 17,274    | 41,811             | 68                    |             |      |                              |               |                 |               |
| 32         | 2.1.2.76251e DOWN             | 605.2005            | 18.91           | 1,219   | 19.855    | 9.331              | 21                    |             |      |                              |               |                 |               |
| 34         | 1.8 331844e DOWN              | 304.1076            | 11:54           | 5,290   | 67,825    | 42,366             | 97                    |             |      |                              |               |                 |               |
| 36         | 1.6 3.84743e DOWN             | 354 1500            | 14.19           | 4,907   | 49,765    | 31,012             | 13                    |             |      |                              |               |                 |               |
| 28         | 1.4.4.02290e-DOWN             | 236.0789            | 11.92           | 6.501   | 57,973    | 41,874             | 43                    |             | P    | w                            | Name          | Adduct          | COMPOSI       |
| - 39       | 1.8 4.65165e DOWN             | 542 1421            | 6.36            | 4,873   | 20,432    | 11.001             | 4                     |             | 1    | 54                           | Add American  | rbMH            | 63428         |











|                             |  | C              | Dut   | pu   | t from Metl   | in         |   |
|-----------------------------|--|----------------|---|------|---|------------|---|
| Mass<br>Tolerance<br>Charge | 187.0976<br>5 PPM \$   | 88306          | [M-H] <sup>-</sup><br><u>m/z</u><br>187.0976<br>M<br>188.1049 | 0    | (+/-)-Ethyl 3-acetoxy-2-methylbutyrate<br>Formula: CBH1604<br>CAS: 139564-43-5                              | in silico  |   |
| Adducts                     | M-H           M-H2O-H           M+OL           M+CI           M+CI | 88254          | [M-H] <sup>-</sup><br><u>m/z</u><br>187.0976<br>M<br>188.1049 | 0    | cis- and trans-Ethyl 2,4-dimethyl-1,3-dioxolane-2-<br>acetate<br><i>Formula</i> : C9H16O4<br>CAS: 6290-17-1 | in silico  | H <sub>3</sub> C O CH <sub>3</sub><br>O O O O O O O O O O O O O O O O O O O |
|                             | M+FA-H<br>M-2H<br>M-3H<br>M+CH3COO<br>M+F                          | 62450          | [M-H] <sup>-</sup><br><u>m/z</u><br>187.0976<br>M<br>188.1049 | 0    | Nonate<br>Formula: C8H16O4<br>CAS:  | (in silico | ньс ин он   |
| Peptides<br>Toxicants       | Add Replides to Search   | 699725         | [M-H] <sup>-</sup><br><u>m/z</u><br>187.0976<br>M<br>188.1049 | 0    | Ethyl 3,5-dihydroxyhept-6-enoate<br>Formula: CBH16O4<br>CAS:  | NO         |   |
| Search                      | zh Cioar   | 712118         | [M-H] <sup>-</sup><br><u>m/z</u><br>187.0976<br>M<br>188.1049 | 0    | Methyl 5-hydroxy-3-oxooctanoate<br>Formula: C9H16O4<br>CAS:   | NO         | че  |
|                             |  | METLIN ID      | Mass  | ΔΡΡΜ | Name  | MS/MS      | Structure   |
|                             |  | Showing 1 to 1 | 0 of 148 entries  |      |   | Previous 1 | 2 3 4 5 15 Next   |











## Use of isotope pattern in identification of metabolites

- Very close in mass, but different in isotope patterns.
- Isotope ratio outlier analysis (IROA)
  - Used for LC-MS (and possibly GC-MS)
  - Designed to distinguish between metabolites of interest and background signals
  - Requires uniform labeling at the 95% and 5% <sup>13</sup>Cenrichment levels



|   | r <mark>ch for eico</mark> s   | sanoid http://www.lip  | pidmaps.  | org  |
|---|--|--|---|--|
|   | latabolitas And Dathways Strategy  |  |   |  |
| PRAPS CIPID P   | letabolites And Pathways strategy  |  |   |  |
|   | Con  | tact   Discussion   Nows   Dublis  | tions   Sit   | o M-   |
| 00  | <u></u>  | tact   Discussion   News   Publica   | ations   Sie  | e ma   |
| 046   | 💁 LIPID M  | etabolites And   |   |  |
| UPID MAP  | Dethurs  | Churcherer   |   |  |
| 000   | Pathway  | ys Strategy  |   |  |
|   | inid classificati  |  |   | om   |
| Fatty Acyls [F  | A) (W)> Eicosanoids [FA  |  |   |  |
| LM_ID   | Common Name  | Systematic Name  | Formula   | Mas  |
| LMFA03000001  | 8(9)-EpETE   | (+/-)-8(9)-epoxy-5Z,11Z,14Z,17Z-   | C20H30O3  | 318.2  |
| LMFA0300002   | 11(12)-EpETE   | (+/-)-11(12)-epoxy-5Z,BZ,14Z,17Z-  | C20H30O3  | 318.2  |
| LMEA03000003  | 14(15)-EpETE   | (+/-)-14(15)-epoxy-5Z,8Z,11Z,17Z-  | C20H30O3  | 318,2  |
| LMFA0300004   | 17(18)-EpETE   | (+/-)-17(18)-epoxy-52,82,112,142-  | C20H30O3  | 318.2  |
| LMFA03000005  | 11(R)-HEDE   | eicosatetraenoic acid<br>11R-hydroxy-12E,14Z-eicosadienoic acid  | ConHasOa  | 324.2  |
| LMFA0300006   | 17R,10S-EpETE  | 17R,105-epoxy-52,02,112,142-   | C20H30O3  | 310.2  |
| LMFA03000008  | 15(R)-HEDE   | eicosatetraenoic acid<br>15R-hydroxy-11Z-13E-eicosadienoic acid  | CanHagQa  | 324.2  |
| LMFA03000009  | 11S-HEDE   | 11S-hydroxy-12E,14Z-eicosadienoic acid   | C20H26O2  | 324.2  |
| LMFA03010000  | Prostanoic acid skeleton   | -  | - 30 - 3  | -  |
|   | 6-keto-PGF1a   | 6-oxo-95,11R,155-trihydroxy-13E-   | C20H34O6  | 370.2  |
| LMFA03010001  |  | and the second s |   |  |
| LMFA03010002  | PGF2a  | 95,11R,15S-trihydroxy-5Z,13E-  | C20H34O5  | 354.2  |
| LMFA03010001<br>LMFA03010002<br>LMFA03010003  | PGF2a<br>PGE2 (W)  | 95,11R,155-trihydroxy-5Z,13E-<br>prostadienoic acid<br>9-oxo-11R,155-dihydroxy-5Z,13E-   | C <sub>20</sub> H <sub>34</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>32</sub> O <sub>5</sub>  | 354.2  |
| LMFA03010001<br>LMFA03010002<br>LMFA03010003<br>LMFA03010004  | PGF2a<br>PGF2 (W)<br>PGD2 (W)  | 95,11R,155-trihydroxy-52,13E-<br>prostadienoic acid<br>9-oxo-11R,155-dihydroxy-52,13E-<br>prostadienoic acid<br>95,155-dihydroxy-11-oxo-52,13E-  | C <sub>20</sub> H <sub>34</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>32</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>32</sub> O <sub>5</sub>  | 354.2<br>352.2<br>352.2                            |
| LMFA030100001<br>LMFA03010002<br>LMFA03010003<br>LMFA03010004<br>LMFA03010005                                 | PGP2a<br>PGE2 (W)<br>PGD2 (W)<br>PGA1  | 95,11R,155-trihydroxy-52,13E-<br>prostadienoic acid<br>9-oxo-11R,155-dihydroxy-52,13E-<br>prostadienoic acid<br>95,155-dihydroxy-11-oxo-52,13E-<br>prostadienoic acid<br>9-oxo-155-hydroxy-102,13E-  | C <sub>20</sub> H <sub>34</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>32</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>32</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>32</sub> O <sub>4</sub>  | 354.2<br>352.2<br>352.2<br>336.2                   |
| LMFA03010001<br>LMFA03010002<br>LMFA03010003<br>LMFA03010004<br>LMFA03010005<br>LMFA03010006                  | PGF2a<br>PGE2 ( <u>W</u> )<br>PGD2 ( <u>W</u> )<br>PGA1<br>PGF2a-d4                | 95, 118, 135-trihydroxy-52, 13E-<br>prostadenoic acid<br>9-oxo-118, 135-dhydroxy-52, 13E-<br>prostadenoic acid<br>95, 135-dhydroxy-11-oxo-52, 13E-<br>9-oxo-135-hydroxy-102, 13E-<br>prostadlenoic acid<br>95, 118, 135-trihydroxy-52, 13E-  | C20H34O5<br>C20H32O5<br>C20H32O5<br>C20H32O4<br>C20H32O4<br>C20H30D4O5  | 354.2<br>352.2<br>352.2<br>336.2<br>358.2          |
| LMFA03010001<br>LMFA03010002<br>LMFA03010003<br>LMFA03010005<br>LMFA03010005<br>LMFA03010005                  | PGF2a<br>PGE2 (W)<br>PGD2 (W)<br>PGA1<br>PGF2a<br>PGF2a<br>PGF2a<br>4              | 95,118,135-trihydroxy-52,13E-<br>prostadenoic acid<br>9-oxo-118,135-dhydroxy-52,13E-<br>prostadenoic acid<br>95,135-dhydroxy-11-oxo-52,13E-<br>prostadenoic acid<br>9-oxo-155-hydroxy-102,13E-<br>prostadenoic acid<br>95,110,135-trihydroxy-102,13E-<br>95,110,135-trihydroxy-102,13E-<br>95,115-dhydroxy-11-0x0-52,13E-  | C20H34O5<br>C20H32O5<br>C20H32O5<br>C20H32O5<br>C20H32O4<br>C20H32O4<br>C20H30D4O5<br>C30H32D2O2  | 354.2<br>352.2<br>352.2<br>336.2<br>350.2<br>356.2 |
| LMFA030130001<br>LMFA03010002<br>LMFA03010003<br>LMFA03010004<br>LMFA03010005<br>LMFA03010007<br>LMFA03010007 | PGF2a<br>PGE2 (W)<br>PGD2 (W)<br>PGD3<br>PGF2a-d4<br>PGD2-d4<br>PGE2-d4            | 95, 118, 155-trillydroxy-92, 136-<br>prostadienoic acid<br>9-oson-138, 155-ddydroxy-92, 136-<br>96, 155-ddydroxy-102, 136-<br>prostadienoic acid<br>9-oson-155-hydroxy-102, 136-<br>prostadienoic acid (3, 4, 4, 44)<br>9-oson-155-hydroxy-102, 136-<br>prostadienoic acid (3, 4, 4, 44)<br>9-3, 136-tdhydroxy-137, 136-<br>prostadienoic acid (3, 4, 4, 44)<br>9-3, 136-ddhydroxy-137, 136-<br>118, 155-ddhydroxy-137, 136-   | C <sub>20</sub> H <sub>34</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>32</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>32</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>32</sub> O <sub>4</sub><br>C <sub>20</sub> H <sub>30</sub> D <sub>4</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>20</sub> D <sub>4</sub> O <sub>5</sub><br>C <sub>20</sub> H <sub>20</sub> D <sub>4</sub> O <sub>5</sub> | 354.2<br>352.2<br>352.2<br>336.2<br>356.2<br>356.2 |
| LMFA03013001<br>LMFA03010002<br>LMFA03010003<br>LMFA03010005<br>LMFA03010005<br>LMFA03010007<br>LMFA03010007  | PGF2a<br>PGE2 (W)<br>PGD2 (W)<br>PGA1<br>PGF2a-d4<br>PGD2-d4<br>PGD2-d4<br>PGE2-44 | 95, 118, 155-trihydroxy-52, 13E-<br>prostadienoic acid<br>9-oxo-118, 155-dhydroxy-52, 13E-<br>prostadienoic acid<br>9-oxo-155-hydroxy-52, 13E-<br>prostadienoic acid<br>95-oxo-155-hydroxy-102, 13E-<br>prostadienoic acid<br>95, 13E-dhydroxy-52, 13E-<br>prostadienoic acid<br>95, 13E-dhydroxy-52, 13E-<br>prostadienoic acid<br>118, 155-dhydroxy-52, 13E-<br>prostadienoic acid<br>118, 155-dhydroxy-52, 13E-<br>prostadienoic acid<br>118, 155-dhydroxy-52, 13E-<br>prostadienoic acid<br>132, 44-dd)  | C20H34O5<br>C20H32O5<br>C20H32O5<br>C20H32O5<br>C20H32O4<br>C20H30D4O5<br>C20H28D4O5<br>C20H28D4O5  | 354.:<br>352.:<br>352.:<br>356.:<br>356.:<br>356.: |













